Game-changing cannabis extract shows promise as schizophrenia treatment

An experimental drug made from a cannabis compound, cannabidiol (CBD), has been found superior to placebo for treating schizophrenia in a mid-stage trial, according to FOX News.

 

The CBD drug was developed by UK-based GW Pharmaceuticals Plc, and the company’s UK-listed shares jumped 12.5 percent since news of this most recent medical trial broke. U.S. listed shares were up by 10 percent.

According to a 24/7 Wall St report, the results of this trial signal a potentially game-changing moment in schizophrenia treatment because “the pharmacology of CBD is distinct from existing anti-psychotic medications, all of which act via effects on dopamine receptors.”

Additionally, CBD treatment shows no serious adverse side-effects, as opposed to existing anti-psychotic medications.

More from 24/7 Wall St:

Professor Philip McGuire, head of the Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, and

...
Rate this article: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.